Semaglutide ya Type 2 Diabetes

Semaglutide ndi m'badwo watsopano wa GLP-1 (glucagon-like peptide-1) analogues, ndipo semaglutide ndi mawonekedwe anthawi yayitali omwe amapangidwa potengera kapangidwe ka liraglutide, yomwe imakhala ndi zotsatira zabwino pochiza matenda amtundu wa 2.Novo Nordisk wamaliza maphunziro a 6 Phase IIIa a jekeseni wa semaglutide, ndipo adapereka fomu yatsopano yolembera mankhwala kwa jekeseni wa semaglutide mlungu uliwonse ku US Food and Drug Administration (FDA) pa December 5, 2016. A Marketing Authorization Application (MAA) inaperekedwanso ku. European Medicines Agency (EMA).

Poyerekeza ndi liraglutide, semaglutide ili ndi unyolo wautali wa aliphatic komanso kuwonjezeka kwa hydrophobicity, koma semaglutide imasinthidwa ndi unyolo waufupi wa PEG, ndipo hydrophilicity yake imakula kwambiri.Pambuyo pa kusintha kwa PEG, sikungangomanga pafupi ndi albumin, kuphimba malo a enzymatic hydrolysis a DPP-4, komanso kuchepetsa kutulutsa kwaimpso, kutalikitsa theka la moyo, ndikukwaniritsa zotsatira za kufalikira kwa nthawi yaitali.